Seropositivity To Tumour Antigens As A Potential New Biomarker For Melanoma Relapse.

e20049 Background: Current prognostic markers fail to identify many patients with stage II / III melanoma who go on to relapse. Immunity has been assumed to play a part in influencing risk of recurrence. We assessed whether seropositivity to a panel of tumour antigens was associated with relapse risk and also measured serum s100 levels and SAA. Methods: 43 melanoma patients with histologically proven, completely resected AJCC stage II n17 (40%), III n 19 (44%) and IV n 7 (16%) disease were recruited. Following informed consent, patients donated 1 serum sample per month for up to 13 months. Seropositivity to NYESO, gp100, Tyrosinase, Mart-1 and MAGE-3 tumour antigens was assessed by ELISA immunoassays (Serametrix). 1stquartile ranges were calculated per antigen. Patients with serum antibody levels u003e 2 x this value were determined seropositive as previously described (Gnjatic et al. 2009). SAA and s100 levels were measured with Hu SAA specific (Invitrogen) and S100 specific (Roche diagnostics) ELISA. The re...